Zubair Malik, MD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Director of the Esophageal Program at Temple University Hospital, offered his thoughts to Healio Gastroenterology about the U.S. Food and Drug Administration’s reintroduction of tegaserod (Zelnorm), a twice-daily oral treatment for irritable bowel syndrome with constipation, for women younger than 65.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH